Neumora Therapeutics, Inc. Common Stock (NMRA)
Automate Your Wheel Strategy on NMRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NMRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NMRA
- Rev/Share 0.0
- Book/Share 1.4144
- PB 0.5288
- Debt/Equity 0.0041
- CurrentRatio 8.9792
- ROIC -1.1977
- MktCap 120971269.0
- FreeCF/Share -1.2304
- PFCF -0.609
- PE -0.4679
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.8479
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NMRA | BofA Securities | Buy | Underperform | -- | $1 | April 2, 2025 |
| Downgrade | NMRA | William Blair | Outperform | Market Perform | -- | -- | March 10, 2025 |
| Downgrade | NMRA | Guggenheim | Buy | Neutral | -- | -- | March 7, 2025 |
| Downgrade | NMRA | Stifel | Buy | Hold | $6 | $2 | March 7, 2025 |
| Downgrade | NMRA | RBC Capital Mkts | Outperform | Sector Perform | $29 | $4 | Jan. 2, 2025 |
| Initiation | NMRA | H.C. Wainwright | -- | Buy | -- | $30 | Oct. 1, 2024 |
News
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128633&wire=1 or contact Joseph E. Levi, Esq.
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Right - NMRA
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128593&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128557&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investor Alert: Robbins LLP Informs Investors of the Neumora Therapeutics, Inc. Class Action
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 10, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023. Neumora is a clinical-stage biopharmaceutical company.
Read More
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128531&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Neumora Therapeutics, Inc.(NMRA) Shareholders
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128508&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
NMRA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (“IPO”) held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072 (S.D.N.Y.), the Neumora class action lawsuit charges Neumora and certain of Neumora's top executives and directors, as well as certain underwriters of the IPO, with violations of …
Read More
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128312&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on Neumora Therapeutics, Inc.(NMRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128298&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) and certain of its officers.
Read More
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128290&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm
Published: February 09, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 9, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"). If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.
Read More
About Neumora Therapeutics, Inc. Common Stock (NMRA)
- IPO Date 2023-09-15
- Website https://www.neumoratx.com
- Industry Biotechnology
- CEO Dr. Daljit Singh Aurora Pharm.D.
- Employees 110